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Abstract
Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV
serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating
a broader range of HCV genotypes and subtypes without being used in combination with interferon and/or ribavirin.
Recently, two crystal structures of the core of the HCV E2 protein (E2c) have been determined, providing structural
information that can now be used to target the E2 protein and develop drugs that disrupt the early stages of HCV infection
by blocking E2’s interaction with different host factors. Using the E2c structure as a template, we have created a structural
model of the E2 protein core (residues 421–645) that contains the three amino acid segments that are not present in either
structure. Computational docking of a diverse library of 1,715 small molecules to this model led to the identification of a set
of 34 ligands predicted to bind near conserved amino acid residues involved in the HCV E2: CD81 interaction. Surface
plasmon resonance detection was used to screen the ligand set for binding to recombinant E2 protein, and the best binders
were subsequently tested to identify compounds that inhibit the infection of Huh-7 cells by HCV. One compound, 281816,
blocked E2 binding to CD81 and inhibited HCV infection in a genotype-independent manner with IC50’s ranging from
2.2 mM to 4.6 mM. 281816 blocked the early and late steps of cell-free HCV entry and also abrogated the cell-to-cell
transmission of HCV. Collectively the results obtained with this new structural model of E2c suggest the development of
small molecule inhibitors such as 281816 that target E2 and disrupt its interaction with CD81 may provide a new paradigm
for HCV treatment.
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Introduction
Hepatitis C virus (HCV) is a global public health problem [1] in
which nearly 85% of affected individuals have acute HCV
infections and exhibit no symptoms. In addition, more than
three-quarters of these cases will advance to chronic disease, which
include liver cirrhosis and liver cancer [2]. The current standard of
care treatment for HCV (Peg-interferon/Ribavirin, PR) can cause
deleterious side effects, and a sustained virologic response (SVR) is
achieved in less than 50% of genotype-1 patients [3]. The FDA
approved protease inhibitors Telaprevir (TVR) and Boceprevir
(BOC) have been shown to provide higher SVR rates in genotype
1 patients [3,4] when each is combined with PR. However the
poor safety profile of TVR and BOC reported in the Week 16
analysis of the French Early Access Program suggest there is still a
need for better HCV drugs [5]. The two most recent FDA
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approvals have been for the oral drugs Simeprevir and Sofosbuvir,
inhibitors that target the HCV NS3/4A protease and polymerase,
respectively [6]. Semiprevir, which needs to be administered with
Ribavirin and Peg-interferon, has a number of undesirable side
effects [7]. The efficacy of Semiprevir has also been shown to be
diminished significantly, due to viral breakthrough (HCV RNA
rebounds and becomes detectable in the patient before treatment
is completed), in patients infected by HCV genotypes 4–6
containing the Q80K, R155K and D168E/V polymorphisms in
the NS3 protease [7]. Recommendations for the use of Sofosbuvir
indicate it should be administered with Ribavirin in HCV
genotype 2 and 3 infections and that Peg-Interferon should be
included in the treatment when infections involve genotypes 1 and
4. While Sofosbuvir is considered the Holy Grail in HCV
treatment by some, it is recommended that treatments be limited
to 12 weeks [6]. Its high cost ($1,000 USD/pill) also puts it out of
reach of many HCV infected patients. This has led many of the
larger pharmaceutical companies to continue developing new
drugs that target one or more steps in the HCV life cycle and block
virus invasion, processing of the pro-protein or replication of the
viral genome.
Since its identification as the first putative receptor for HCV [8],
the tetraspanin CD81 has been demonstrated to be a key player in
HCV entry [9]. In particular, its large extracellular loop (CD81-
LEL) is involved in the binding to the HCV envelope glycoprotein
E2 [10,11]. Zhang et al. [12] elucidated a separate, additional
function for CD81 in the HCV life cycle. These studies revealed
that CD81-LEL is important for efficient HCV genome replica-
tion. In addition, the E2-CD81-LEL interaction has been
determined to induce several immuno-modulatory effects such as
the production and release of pro-inflammatory cytokine gamma
interferon from T-cells. In addition, this interaction has also been
shown to down regulate T-cell receptors and suppress the activity
of natural killer (NK) cells [13]. Therefore, it is tempting to
speculate that blocking the CD81-LEL:HCV E2 interaction might
also contribute to arresting disease progression to liver cirrhosis.
Following the discovery of the E2 glycoprotein’s role in HCV
infection and disease progression, several approaches have been
used to attempt to develop anti-HCV drugs and vaccines that
target the HCV E2 glycoprotein [14–17] located on the surface of
viral particles. These efforts have had to deal with challenges that
relate to the genomic diversity and heterogeneity of HCV,
limitations in animal models used to test vaccines and drugs,
and the lack of a resolved crystal structure for the HCV E2
glycoprotein. Recently, two crystal structures have been reported
for the core ectodomain of the HCV E2 protein [18,19]. Kong
et al. [18] obtained the structure of amino acid residues 384–746
(E2c) by designing and expressing 41 soluble HCV E2 constructs
and selecting 15 to screen against E2-specific Fab fragments in
crystallization trials. Using a combination of x-ray crystallography
and negative stain-electron microscopy, Kong et al. [18] discov-
ered the structures they obtained for E2 were globular and very
different from the predicted models of E2 that were created using
class II fusion protein templates containing three b-sheet domains.
Additionally, they were able to identify key CD81-binding residues
through mutational studies. Important CD81 binding sites were
determined to be in the epitope recognized by the neutralizing
antibody AR3C, along one side of the b-sandwich (an isolated
region of the CD81-binding loop) and a front layer consisting of
loops, short helices and b-sheets [18–20]. AR3C was also found to
cross-neutralize HCV genotypes by blocking CD81 binding to
HCV E2 [21]. A second structure was reported for E2c (amino
acid residues 492–649) by Khan et al. [19]. This new structure,
which was obtained by crystallizing E2c in complex with a Fab
fragment of the mouse monoclonal antibody 2A12, is very similar
to the previously reported structure. In addition to providing a
second structure for the E2 core from a different HCV genotype
(2a), new information was also reported on the accessibility of the
E2 core amino acids within the structure using a combination of
limited proteolytic degradation and deuterium exchange.
Despite the advances that have been made in the field of HCV
drug development, our current drugs offer little protection against
the emergence of genetic variants (escape variants) of HCV – a
feature of HCV biology that complicates both drug and vaccine
development. Drugs that target only one step in the HCV life cycle
will be the least effective in treating patients that become infected
with these emerging variants. The FDA approved drugs for HCV
are good examples, as they are only effective against a subset of
genotypes. In an effort to identify a suitable drug candidate that
targets the majority of the existing HCV genotypes, we created an
HCV E2 homology model based on the new HCV E2 core crystal
structure reported by Kong et al. [18] that contains three peptide
segments that were not present in the reported structure, and we
have used this model to identify small molecule drug leads that
target highly conserved sites on the HCV E2 glycoprotein located
within the region bound by CD81. AutoDock was used to perform
virtual screening runs against 1,715 small molecules and 34 of the
best compounds were tested experimentally using surface plasmon
resonance (Biacore T100) to identify a set of small molecules that
bind to the recombinant E2 protein. The compounds showing
binding activities were then tested for their ability to block HCV
infection of Huh-7 cells. One compound, 281816, was found to
block infection of the cells by each of the HCV genotypes and
subtypes tested (1a, 1b, 2a, 2b, 4a and 6a) in a dose-dependent
manner. Experiments with Huh-7 cells have shown that both
mechanisms that lead to HCV infection, cell-free and cell-to-cell
transmission, are abrogated by 281816. Inhibition of cell-free
infection is limited to the viral attachment step, as well as
interactions occurring during viral internalization and fusion;
281816 appears to have no effect on post-entry processes.
Materials and Methods
Creation of the homology model of E2 used for docking
A crystal structure of E2c deposited in the PDB under a code
4MWF was solved by Kong et al. [18] at a resolution of 2.65
Angstroms. However, upon examination of the structure file prior
to docking, the set of reported atom coordinates of the protein was
found to be incomplete. In addition to the coordinate file
containing structural information for only 171 residues out of
the 363 amino acids present in the full-length protein, structural
information was missing for several peptide segments or loops
within the structural core of the protein. In order to prepare a
more complete version of the structure for docking, we have
performed several homology modeling and structure analysis tasks
using the coordinates of E2c as a template. The final structural
model was created using the AS2TS system [21] based on atom
coordinates from the PDB chains 4mwf_C and 4mwf_D and
extensively manually edited. A structural search for similar
fragments in proteins in the PDB that could be used to model
missing loop regions was performed using the StralSV algorithm
[22], which identifies protein structures that exhibit structural
similarities despite low primary amino acid sequence similarity.
The side-chain prediction was accomplished using SCWRL [23]
when residue-residue correspondences did not match. Residues
that were identical in the template and E2 protein were copied
from the template onto the model. Potential steric clashes were
identified in the unrefined model using a contact-dot algorithm in
Novel HCV Drug Lead Targeting the E2 Glycoprotein
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the MolProbity software package [24], and the constructed model
was finished with relaxation using UCSF Chimera [25].
Virtual screen of the NCI Diversity Set III to the HCV E2
protein model
AutoDock VINA 1.1.2 (VINA) [26] was used to perform a
virtual screen of the NCI Diversity Set III against the homology
model that was created using the new crystal structure solved by
Kong et al. [18] (PDB ID: 4MWF) as a template. The model of
the protein was prepared for docking using the MolProbity Server
(to add all of the hydrogen atoms and to flip the HIS/ASN/GLN
residues if doing so significantly lowered the energy) and
AutoDockTools 4.2 (which added the Gasteiger-Marsili charges
and merged the non-polar hydrogens onto their respective heavy
atoms) [27,28]. The NCI Diversity Set III library containing 1,715
models of compounds was obtained from the ZINC server (http://
zinc.docking.org) [29]. The multi-molecule ‘‘mol2’’ files from
ZINC were prepared for docking calculations using Raccoon [30],
which added the Gasteiger-Marsili charges, merged the non-polar
hydrogen atoms onto their respective heavy atoms, and deter-
mined which bonds should be allowed to freely rotate during the
calculations, to generate the ‘‘pdbqt’’ docking input format.
Four different, overlapping grid boxes were used in this virtual
screen to enable the docking calculations to explore almost the
entire surface of this E2 model. Those amino acids missing from
the E2c crystal structure whose modeled coordinates were known
with the lowest degree of certainty, such as residues E454 and
L456–E482 located in the large missing loop and residues G575–
L580 and F586–K588 in the two other two missing segments, were
not included in the boxes. By defining the boxes to exclude these
residues, we were able to minimize the impact of these less
accurate parts of the model on ligand docking. Since large grid
boxes were used in these calculations, the ‘‘exhaustiveness’’ setting
in VINA was increased to 20. Each calculation used 8 CPUs on
the Linux cluster at Rutgers University-NJMS. The first box,
which included P490, was centered at 38.829, 12.968, 240.958 (x,
y, z) and had the following dimensions: 24.0635.0630.0 (x, y, z in
Angstroms). The second grid box, which included G436, was
centered at 48.401, 11.791, 214.449 and had a size of:
32.0636.0624.0. The third grid box, which included S528, was
centered at 51.644, 25.877, 227.795 and encompassed
30.0630.0630.0 Angstroms3. The fourth grid box, which was
selected to include the side of E2 not covered by the previous three
grid boxes, was centered at 57.777, 12.968, 234.067 and enclosed
24.0635.0632.0 Angstroms3.
The docking outputs generated by VINA were processed and
filtered using python scripts from Raccoon2 and Fox [30]. The
top-ranked VINA mode from each docking calculation was
harvested, and 17 different sets of energetic and interaction-based
filters (Table 1) were investigated to harvest the most promising
docking results for visual inspection. Different sites have different
numbers and arrangements of hydrogen bond donors, hydrogen
bond acceptors, and aromatic rings. They also have very different
geometries (i.e., van der Waal surfaces and solvent accessibility
patterns and percentages). Consequently, several different filters
were tested for the docking results against each site in order to
harvest a’’reasonable’’ number of docked modes for visual
inspection against each site. This is a subjective process, guided
by extensive experience with virtual screening. If the same filters
are used against each site, then for some sites (or for filters that are
not restrictive enough), too many compounds are obtained for
visual inspection (i.e., the process is less efficient and a larger
number of false positive results are likely to occur). For other sites
(or for filters that are too restrictive), an insufficient number of
compounds will be obtained for visual inspection. This would
increase the chance of missing promising candidates (having too
many false negatives) [31]. The following parameters were
explored in the filtering process: -e indicates the minimum
estimated Free Energy of Binding from the VINA score in kcal/
mol, -l is the minimum ligand efficiency value in kcal/mol/heavy
atom, -S is the minimum number of hydrogen bonds between the
ligand and target, and -H indicates that the ligand had to form a
hydrogen bond with either a backbone amino group (::N) or a
backbone carbonyl oxygen (::O) of any residue in that grid box.
For the results with grid box 1, filters 12 and 13 each harvested
70 and 51 compounds, respectively. Those filtered sets were
pooled together to form a set of 96 unique compounds for visual
inspection. Filters 14 (which harvested 11 compounds), 15 (which
harvested 21 compounds), and 1 (which harvested 34 compounds)
were pooled together from the results with grid box 2, in order to
identify 52 compounds for visual inspection. Similarly, for the
results with grid box 3, filters 1 (which harvested 25 compounds),
14 (which identified 20 candidates), and 15 (which harvested 13
compounds) were pooled to obtain 34 compounds for visual
inspection. To identify candidates in the results with grid box 4,
filters 1 (which harvested 26 compounds), 14 (which harvested 19
compounds), and 15 (which harvested 14 compounds) were pooled
to obtain 42 compounds.
These four different pools of potentially promising compounds
were then visually inspected to select the ligands to be tested
experimentally for binding to recombinant E2 protein. Both the
structure of the compound and the nature of its predicted
interaction with the protein were examined. Compounds were
considered good hits and suitable for testing if they 1) were small
(molecular weight,200–600 Da), 2) contained a single free amine
or carboxyl to facilitate their potential conjugation to other
ligands, 3) were not highly charged or highly hydrophobic, 4) did
not contain iodine, disulfide bonds or highly reactive functional
groups, 5) did not contain multiple conjugated aromatic ring
systems, 6) exhibited multiple contacts to the protein surface, and
7) had conformers that bound to the protein surface near one or
more E2 amino acid residues that have been shown to participate
in or be required for binding to CD81. Detergent-like molecules
were avoided and only commercially available compounds were
considered for screening.
Expression and purification of the HCV E2 protein
Con1eE2
A construct containing a sequence encoding amino acids 384–
656 of the Con1 envelope protein 2 ectodomain (eE2) [19], a
genotype 1 E2 sequence, was cloned into a lentiviral expression
vector containing a carboxy-terminal Protein A tag separated by a
PreScission Protease cleavage consensus sequence. eE2-ProtA was
stably expressed in HEK293T cells using lentiviral infection. The
protein was secreted into the media and supernatants were
purified using IgG Sepharose (GE Healthcare, Piscataway, NJ).
eE2-ProtA was eluted with 100 mM sodium citrate and 20 mM
KCl at pH 3 directly into tubes containing 1M Tris pH 9 for
immediate neutralization. PreScission Protease (GE Healthcare,
Piscataway, NJ) was added to the eluted sample at a ratio of 1:50
(enzyme:eE2), and the digest was then dialyzed into 20 mM
HEPES pH 7.5, 250 mM NaCl, 5% glycerol. eE2 was separated
from the cleaved tag and the PreScission Protease by ion exchange
chromatography [19].
Novel HCV Drug Lead Targeting the E2 Glycoprotein
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Experimental analysis of ligand binding to recombinant
E2 and CD81-LEL by surface plasmon resonance (SPR)
detection
A set of 34 of the ligands predicted by AutoDock to bind to E2
were tested experimentally to determine if they bound to
recombinant E2 protein immobilized on a chip using surface
plasmon resonance detection. The SPR analyses were performed
using a Biacore T100 workstation (GE Healthcare, NJ, USA) and
recombinant HCV E2 protein. 1 mM HCV E2 was diluted into
10 mM sodium acetate buffer pH 5 and immobilized for 15 min
at a flow speed of 5 ml/min onto a CM5 sensor chip using amine
coupling (EDC-NHS). Approximately 10,000 response units (RU)
of protein were immobilized on the chip. His-CD81-LEL
(Bioclone Inc., San Diego, CA) binding to HCV E2 was tested
as a positive control prior to injecting the ligands to confirm the E2
protein was functional and would bind CD81-LEL. In a typical
experiment with CD81, 1 ml of his-CD81 (50 nM) in 114 ml PBS
was injected into channel 2 and 106.4 RUs of CD81 bound to the
E2 on the chip. This was followed by testing the binding of the 34
virtual screening hits where the ligands were prepared as 200 mM
solutions in PBS and they were introduced to the protein using a
pre-programmed 3 min association and 1 min dissociation inter-
val. The response was measured at two time points during
dissociation, 10 and 50 seconds, to obtain information on the rate
of ligand dissociation from E2.
Two single cycle kinetic studies were also performed to compare
the binding of 281816 to the recombinant E2 and his-tagged
CD81-LEL proteins. In both studies, the proteins were diluted to a
concentration of 1 mM in 10 mM sodium acetate buffer pH 4.5
and immobilized for 15 min on a CM5 sensor chip using amine
coupling (EDC-NHS). Data on the kinetics and affinity of 281816
binding was obtained by flowing five concentrations of the 281816
ligand (2.5 mM, 7.4 mM, 22.2 mM, 66.7 mM and 200 mM) over
the chip sequentially at a flow rate of 30 ml/min. Equilibrium
binding curves were generated for each protein and the data were
fitted using a monovalent binding model to determine the Kd for
281816 binding to E2 and CD81-LEL.
HCV infection assays
Pseudotyped retroviral particles harboring HCV envelope
proteins (HCVpp) from different genotypes were produced as
described previously [32,33] with plasmids kindly provided by F.L.
Cosset, J. Ball, and R. Bartenschlager. A plasmid encoding the
feline endogenous virus RD114 glycoprotein [34] was used for the
production of RD114pp. Both HCVpp and RD114pp expressed
Firefly luciferase.
The cell culture-produced HCV particles (HCVcc) used in this
study were based on the JFH1 strain [35] and were prepared as
described previously [36,37]. They were engineered to express the
A4 epitope, titer-enhancing mutations and Gaussia luciferase
[36,37].
To identify ligands that inhibit HCV infection, Huh-7 cells were
seeded in 96-well plates and treated the day after with six different
concentrations of each ligand diluted in DMSO in duplicate using
a Zephyr automated liquid handling workstation (Caliper BioSci-
ences, Hopkinton, MA). The final concentration of DMSO (1%)
was adjusted to be the same for all ligand concentrations. Cells
treated with DMSO were used as negative controls. Cells treated
with different concentrations of anti-CD81 antibody (JS-81 from
BD Pharmingen, San Jose, CA) 1 hr before infection, were also
used as positive controls. The third day, RD114pp, HCVpp or
HCVcc were inoculated and incubated for 30 hr at 37uC. Firefly
and Gaussia luciferase assays were performed as indicated by the
manufacturer (Promega, San Luis Obispo, CA).
The analysis of the effect of the 281816 ligand on Huh-7
infection by HCVpp bearing envelope proteins from different
genotypes was performed in 24-well plates using the method
described above. This ligand was also screened for toxicity to the
cells using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) assay [38] and
Table 1. Energetic and interaction-based filters used to harvest the most promising results from the ligand docking runs.
Filter Parameter Set
1 -e 26.5 -l 20.29 -S 3
2 -e 27.0 -l 20.29 -S 3
3 -e 27.5 -l 20.29 -S 3
4 -e 28.0 -l 20.29 -S 3
5 -e 27.0 -l 20.29 -S 4
6 -e 27.5 -l 20.29 -S 4
7 -e 28.0 -l 20.29 -S 4
8 -e 26.5 -l 20.29 -S 3 -H ::N
9 -e 26.5 -l 20.29 -S 3 -H ::O
10 -e 27.0 -l 20.29 -S 3 -H ::N
11 -e 27.0 -l 20.29 -S 3 -H ::O
12 -e 27.0 -l 20.29 -S 4 -H ::N
13 -e 27.0 -l 20.29 -S 4 -H ::O
14 -e 27.0 -S 3 -H ::N
15 -e 27.0 -S 3 -H ::O
16 -e 27.0 -S 4 -H ::N
17 -e 27.0 -S 4 -H ::O
doi:10.1371/journal.pone.0111333.t001
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was found to not be toxic under the conditions used in the
infection assays.
Inhibition of recombinant E2 binding to native CD81
Two different assays were performed to test for the inhibition of
E2 binding to CD81 by 281816. In a cell binding assay, the
human B cell line Raji (ATCC, Manassas, VA), which expresses
high levels of CD81 on its surface [39,40], was used to determine if
ligand 281816 inhibits the binding of HCV-E2 protein to native
human CD81. Purified HCV-E2 protein (4 mg) was pre-incubated
with 1,5,15, 50, 100 or 400 mM of the ligand 281816 for 25 min at
RT. After pre-incubation the E2-ligand complex was added to the
cells and incubated for 25 min. The complexes were washed from
the cells and 0.5 mg of mouse anti E2 antibody (clone H53) was
added followed by a FITC-conjugated anti-mouse antibody
(Southern Biotechnology, Birmingham, AL). The cells were
washed, fixed with 3% paraformaldehyde, and analyzed by flow
cytometry (BD FACSCalibur, software: Cell Quest Pro). The
mean fluorescence intensity (MFI) was calculated using Flowjo
software (TreesStar, www.flowjo.com).
The second test used an ELISA assay to determine if E2 binding
to a recombinant CD81 protein is inhibited by the presence of
ligand 281816. In this assay, a 96 well plate was coated with GST-
tagged human CD81-LEL (5 mg/ml) overnight as previously
described [10], then washed with PBS, 0.5% Triton X-100 and
blocked with 2% milk in PBS for 1 hr. HCV E2 protein (5 mg/ml)
was pre-incubated with different concentrations of 281816 for
30 min before adding to the plate, then HCV-E2 protein (with or
without the ligand) was added to the GST-tagged human CD81-
LEL coated plate and incubated for 1 hr at room temperature to
allow the protein to bind. To detect HCV-E2 binding, a primary
mouse anti-E2 antibody (H53 clone, 5 mg/ml) was added and
incubated for 1 hr followed by a secondary goat anti-mouse-horse
radish peroxidase (HRP) antibody (Southern Biotechnology
Associates, Birmingham, AL) diluted 1:5000. Substrate was added
(citrate buffer pH 4.0, 3.5 ml hydrogen peroxide and 100 ml 2,2’-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) and the absor-
bance was measured at 405 nm.
Inhibition of anti-CD81 5A6 antibody binding to CD81-
LEL
To determine if ligand 281816 binds to the E2 binding site on
CD81, a competition binding experiment was run using the ligand
and an anti-CD81 antibody (5A6 clone) that has been shown
previously to block E2 binding [57,58]. In this assay, a 96 well
plate was coated with GST-tagged human CD81-LEL overnight
and then blocked with 2% milk in PBS for 1 hr at RT. The plate
was then incubated for 40 min with 281816 (1 mM) or PBS as a
control. The indicated concentrations of mouse anti-human CD81
antibody (5A6) were added to the plate and incubated for an
additional 1 hr, followed by anti-mouse IgG-HRP. The absor-
bance was then measured at 405 nm.
HCVcc cell-to-cell transmission assay
Cell-to-cell transmission was measured as described previously
[41,42]. Briefly, Huh-7 cells were seeded on coverslips and
infected at low multiplicity of infection with HCVcc for 2 hr at
37uC. After washing, cells were cultured in medium containing
neutralizing anti-E2 antibody (3/11; 50 mg/ml) to block cell-free
transmission and 281816 at the indicated concentrations. Cells
cultured in the presence of DMSO or Epigallocatechin-3-gallate
(EGCG, 50 mM) [42] were used as negative and positive controls
of inhibition, respectively. Three days post-infection, cells were
fixed with formalin solution (formaldehyde 4%, Sigma, St Louis,
MO) and stained by indirect immunofluorescence using the anti-
E1 monoclonal antibody A4 and Alexa555-conjugated anti-mouse
immunoglobulins. Cell-to-cell transmission was quantified by
counting the number of infected cells per focus. As a control,
cells were infected with HCVcc pre-incubated with 50 mg/ml 3/
11 antibody to confirm cell-free transmission is blocked by the
antibody as reported previously [41].
Kinetics of entry
Cells treated with 281816 at 10 mM or with DMSO were
infected with HCVcc for 1 hr at 4uC (attachment/binding period).
Virus was removed, cells were washed with medium and
incubated again for 1 hr at 4uC (post-attachment/binding period).
Cells were then washed and incubated for 1 hr at 37uC
(endocytosis/fusion period). Lastly, cells were washed and
incubated in complete culture medium for 21 hr. Infection levels
were monitored by measuring luciferase activities. To confirm
281816 was not toxic to the cells, an MTS assay [38] was also
performed after incubating the cells with 10 mM 281816 for the
same lengths of time (1 hr, 2 hr or 3 hr) the ligand was exposed to
the cells in the entry experiments.
Antibodies
Mouse anti-E1 A4 [43], anti-E2 H53 [44] and rat anti-E2 3/11
[45] were produced in vitro using a MiniPerm apparatus
(Heraeus). FITC-conjugated and Alexa555-conjugated anti-mouse
immunoglobulins were obtained from Southern Biotechnology
(Birmingham, AL) and Jackson Immunoresearch (West Grove,
PA), respectively.
Results
Structural model of E2
In order to maximize the likelihood that these experiments
would lead to the discovery of small molecules that bind to E2 and
block E2’s binding to CD81, we created a homology model of the
core of the E2 protein to use as our docking target. This model was
created using the HCV genotype 1a protein sequence
NP_751921.1, which corresponds to isolate H77, and the crystal
structure of E2c as the primary template (PDB entry: 4MWF).
Using a model, rather than the E2c crystal structure, was
important because the reported crystal structure of E2c has three
large gaps in which atom coordinates for 57 amino acids, or one
quarter of the E2c structure, is missing. The coordinates listed in
PDB chains 4mwf_C and 4mwf_D provide structural information
for only 169 and 171 residues respectively out of the 363 amino
acids present in the full-length E2 protein. Within each of the
deposited PDB chains, three stretches of amino acid sequence
(large loop P453-P491 containing 39 amino acids, T542-G547 or
V574-N577, and F586-R596) are missing from the structure
(Figure 1A). Docking to structures lacking such a large proportion
of their amino acids can be problematic because the missing
peptide segments are usually located on the protein’s surface, and
the underlying amino acid residues packed in the interior of the
protein are exposed and incorrectly presented as the surface
during the docking. Unfortunately, similar regions are also not
present in the crystal structure of the genotype 2a HCV E2c
protein (PDB chain: 4nx3_D) reported by Kahn et al. [19] which
provides atom coordinates for only 119 amino acids. Structural
superposition of 4mwf_C and 4nx3_D (Figure 1B) shows strong
conformational similarities between the experimentally solved
structures of the E2 proteins with a root mean square deviation of
1.07 Angstroms measured on 98 residues for which distances
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between corresponding Ca atoms are under 3 Angstroms. The
most significant structural deviations are observed in the region
566–601 (numbering from 4mwf_C) which corresponds to the
region that also exhibits the greatest variation in sequence (see
sequence alignment in Figure 1A).
Exhaustive structure similarity searches of 90 residue structural
fragments of E2 conducted using the entire PDB database
(255,302 PDB chains) revealed that no additional structural
homologs could be found at the level of calculated structure
similarities by LGA score [46] higher than LGA_S = 45%,
suggesting that the HCV E2 protein represents a novel fold in
the current PDB. Thus, the modeling of the structure of the
insertions needed to fill in missing regions in the experimentally
solved structures and to complete the model was a difficult task,
and it was completed with a very low degree of confidence. By
applying a combination of structural modeling and analysis
methods to the E2 crystal structure (see Materials and Methods
section), we were able to construct a model (Figure 2) that contains
the 57 amino acids that are missing in the E2c structure, including
an amino acid known to be critical for E1 binding (W487), key
amino acids known to participate in CD81 binding (Figure 1C), as
well as the exact sequence for the HCV genotype 1a E2 protein.
Three regions of the protein that have been identified by others to
be critical for E2 binding to CD81 [47–49] are contained in the
model in their entirety. Currently, however, only three of the
twenty-one Region 1 amino acids (H421–N423) are present in the
model. A comparison of our model to the two E2c structures (see
bar plots in Figure 1A and superposition of the E2c structure and
the model in Figure 2) shows the main core regions are, as one
would expect, very similar. The differences that are observed in
the core region are small and appear to reflect only minor local
deviations between experimentally solved structural templates.
The large region that does differ corresponds to the missing
peptide segments.
Ligands predicted to bind to CD81 binding sites on E2
Five ligand-binding sites on the HCV E2 homology model
(Figure 3) were identified by docking the National Cancer
Institute’s Diversity Set III library of ligands to the E2 model.
Each of these sites is associated with or positioned next to one or
Figure 1. Comparison of structural templates used for modeling the HCV E2c protein. (A) Bar representation of E2 sequence showing the
structural similarities between crystal structures 4MWF chains C and D (E2c structure, genotype 1a), and 4NX3 chain D (genotype 2a). Regions
reported in the coordinates span amino acid residues from H421 to N645. The percent sequence identities between amino acid sequences taken from
coordinates and corresponding sequence fragments from HCV E2 protein of genotype 1a are shown in the column Seq_ID. In green are colored
regions where structural deviations are below 3 A˚ngstroms measured as Ca-Ca distances between corresponding residues from the superimposed
structures. In red are regions where structural data is missing or deviations are greater than 3 Angstroms. The locations of amino acid residues that
have been reported to be important for E2 binding to CD81 are marked with yellow stars. (B) Structural superposition of 4mwf_C and 4nx3_D shows
strong conformational similarities between experimentally solved structures of E2 proteins for which the level of sequence identity is 69%. In blue
and purple are colored structural fragments where two structures 4mwf_C (566–601; Blue: light-dark) and 4nx3_D (568–605; Purple: light-dark)
significantly differ. (C) Surface presentation of the 4mwf_D structure showing the amino acid residues identified to be important for E2 binding to
CD81 (yellow). The other amino acid residues are color coded with the most hydrophilic residues being colored blue, the most hydrophobic residues
colored red orange, and intermediate residues colored white.
doi:10.1371/journal.pone.0111333.g001
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more of the amino acid or peptide sequences that have been
identified by others to either participate in E2 binding to CD81,
E2 binding to E1, or to be important for HCV infectivity. While
the accuracy of the structure of the modeled segments missing
from E2c may be low, the docking and visual inspection processes
focused on the regions of the target that were based on the crystal
structure. The majority of the amino acids that make up or
surround each of the cavities used for ligand docking and the
neighboring amino acids that play a role in E2 binding to CD81
are all located in the core region of E2. The structure of this region
of the model is known with high confidence, as it is essentially
identical to the two recent crystal structures of the E2 protein core
determined by two different groups [18,19]. The locations of the
grid boxes were also defined in such a manner that the amino
acids in the modeled segments missing from the crystal structure of
E2c would only be marginally considered during the docking.
Only those residues in close contact with the core E2c structure
were included in the boxes. In this way, the regions of the
homology model with the least well-defined structures had a
minimal impact on the docking results.
The first sequence of importance is the peptide segment Q412–
N423 that was identified to bind to the broadly neutralizing
antibody AP33 [20,50]. Alanine mutagenesis studies have shown
all of the amino acids in this region appear to be important for
HCV infectivity [48]. The model used in this study currently
contains only three of the amino acids that correspond to this
segment, H421, I422 and N423. Sequence 2 spans the second
hyper-variable domain of E2, extending from amino acid Y474 to
R492 [13,47–49]. The majority of amino acids in this sequence
have been shown to have no effect on E2 binding to CD81 when
mutated [51], but antibodies binding to this region of the protein
do inhibit HCV infectivity [49] and CD81 binding [50]. One
amino acid located within sequence 2, W487, does however
appear to be critical for E2 binding to E1. This amino acid is the
first residue in one of the WHY motifs that have been reported to
play a role in E1:E2 dimerization [47]. The third sequence spans
amino acids S522–G551 [20,47–49] and the fourth sequence of
importance is comprised of amino acids P612–P619 [49].
Mutations of residues Y527, W529, D535, Y613, R614, W616,
H617 and Y618 in these two regions have all been shown to
eliminate E2 binding to CD81 [47,49]. Mutating all but three of
these amino acids (D535, R614 and W616) appears to eliminate
specific interactions with CD81. W616 is the first amino acid in
another WHY motif that is located in a region (G600–C620) that
has been shown to be involved in fusion [52]. Alanine mutagenesis
of D535, R614 and W616 was found to disrupt the structure of the
AR3A epitope and indirectly impact CD81 binding [49].
These five binding sites were used to guide to our selection of
the top virtual screening hits to be tested experimentally for
binding to recombinant E2 protein. All five sites are cavities in the
protein surface that would be expected to be accessible to ligands
because they contain or are surrounded by amino acid residues
known to participate in E2 binding to CD81 or they are located
within the epitopes of antibodies that inhibit HCV infectivity or
block CD81 binding. While there is still some debate regarding the
importance of the entire regions bound by neutralizing antibodies,
amino acid mutagenesis studies have provided a great deal of
insight into those amino acids located within the epitopes that
participate in E2 binding to CD81. Based on this information, we
have used the set of amino acids W420–I422, S424, G523, Y527,
W529, G530, D535, P612–R614 and W616–P619, whose
mutation has been shown to eliminate E2 binding to CD81, to
identify locations within these sites (Figure 3) where ligand binding
would be expected to disrupt E2’s ability to bind to CD81.
Figure 2. Comparison of the crystal structure of E2c with the homology model. Structural superposition between E2c crystal structure from
the PDB chain 4mwf_D (red) and the homology model (black) is illustrated using a ribbon representation. The crystal structure and homology model
overlap in most of the regions, except the fragments where coordinates in the experimental structure are missing (red dashed lines).
doi:10.1371/journal.pone.0111333.g002
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Thirty-four of the highest scoring ligands were selected from the
docking run for experimental analysis. Docked conformations of
each of the ligands were predicted to bind to one or more of these
five binding sites. The best ligands were considered to be those
that exhibited the lowest free energy of binding and were predicted
to interact with or bind nearby one or more of the E2 amino acids
within the sites that were reported to be critical for E2 binding to
CD81. The free energy of binding predicted for the best bound
ligand conformations, shown in Table 2, ranged from 26.2 to 2
8.7 kcal/mol. Additional criteria used to select among the group of
ligands predicted to bind include the number of contact points/
interactions (such as hydrogen bonds, salt bridges, van der Waals
interactions) with amino acids in the model (the larger number of
contacts or interactions the better) and the chemical structure of
the ligands (preference is given to those that contain a free amino
or carboxyl group that is exposed to solvent). Ligands with free
amino or carboxyl groups can easily be linked to other ligands to
create higher affinity or more selective second-generation inhib-
itors. Compounds that have been reported previously to be highly
toxic were excluded.
Experimental confirmation of ligand binding to HCV E2
Each of the 34 ligands was tested experimentally using surface
plasmon resonance (SPR) detection (on a Biacore T100 instru-
ment) to determine if it would bind to recombinant HCV E2
protein and to obtain an assessment (relative to the other ligands)
of how well it binds. Twenty-three of the molecules provided a
positive change in response units (RUs) indicating they bound to
the E2 protein immobilized on the chip (Table 3). The measured
responses for the ligands that bound varied from 54 to 276 RUs.
Data was also obtained on the rate of ligand dissociation by
measuring the amount of ligand remaining bound at two time
points, dissociation 1 (10 seconds) and dissociation 2 (50 seconds),
during the rinsing of the chip with buffer (Figure 4). The majority
of the ligands dissociated quickly, as one might expect for small
molecules that bind to the surface of a protein. A few, such as
ligands 121861, 4429, 158413, 81462, and 57103, exhibited
slower off rates when compared to others.
Inhibition of HCV entry
The 23 compounds that were observed to bind to recombinant
E2 protein were then tested to determine if they would block HCV
infection of Huh-7 cells. Pseudotyped retroviral particles harboring
the envelope protein of an endogenous feline retrovirus
(RD114pp) were first used to determine the specificity and the
safety of molecules. We excluded from a further characterization
the molecules for which the half maximal inhibitory concentration
(IC50) against RD114pp was lower than 10 mM or the molecules
that significantly increased RD114pp infection (Table 4). The
remaining ligands were next tested against pseudotyped retroviral
Figure 3. Location of ligand-binding sites on the E2 homology
model used to select ligands for testing. Each of these sites either
covers or is located immediately adjacent to amino acids or peptide
segments of the E2 protein known to be important for HCV infectivity.
H421–N423 (yellow): each amino acid in this region is important for
infectivity. Antibodies binding to amino acids Y474–R492 (light cyan)
have been shown to prevent infectivity, but this region of the protein
has no effect on E2 binding CD81. W487 (dark cyan) is a key amino acid
that is involved in E2 binding to E1. S522–G551 (light green) and Y527
and W529 (dark green) are critical for E2 binding to CD81. Site 4: P612,
Y613, and H617–P619 (red) are critical for E2 binding to CD81;
mutations to R614–W616 (pink) disrupt the structure of the region.
The four views show the structure as it is rotated counterclockwise from
left to right. Movie S1 shows the rotating structure.
doi:10.1371/journal.pone.0111333.g003
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particles harboring genotype-2a HCV envelope proteins (HCVpp
2a), cell culture produced HCV particles (HCVcc) or RD114pp.
As a positive control, an anti-CD81 antibody (JS-81) was included
in the assays. One compound, 281816, showed an inhibitory effect
on both HCVpp and HCVcc infection with IC50’s of 1.02 mM
and 3.95 mM, respectively (Table 4 and Figure 5A), indicating
that this molecule inhibits the entry step of the HCV lifecycle,
probably through a specific effect on the virus’s interaction with
CD81. Huh-7 cell toxicity was not observed over the range of
ligand 281816 concentrations tested in these assays.
To determine if 281816 would inhibit HCV genotypes other
than 2a, a series of infection assays was performed with HCVpp
bearing envelope proteins from a number of different HCV
genotypes. Interestingly, 281816 was found to be equally effective
in inhibiting Huh-7 infection by all the HCV genotypes tested (1a,
1b, 2a, 2b, 4a and 6a, Figure 5B). The IC50 values ranged from
2.2 mM to 4.6 mM (Table 5).
To confirm that 281816 inhibits HCV entry with no further
effect on post-entry steps, 281816 (10 mM) was added at different
time points (Figure 6A) before (22 to 0 hr, b), during (0 to 2 hr, c),
or after (2 to 24 hr, d) inoculation of Huh-7 cells with HCVcc, as
previously described [53]. Cells treated with dimethylsulfoxide
(DMSO) and cells treated continuously (22 to 24 hr, a) with
281816 were used as controls. The results clearly showed that
281816 significantly inhibits HCVcc infection when present
during virus infection (Figure 6A, c). The decrease in HCVcc
infection that was observed in condition b is likely to be due either
to some 281816 remaining bound to the cell after the washing step
or its entering into the cells and acting on the entry step
(Figure 6A, b). Similarly, a slight decrease was also observed in
condition d (Figure 6A), which is likely related to 281816 acting on
the entry of the remaining particles (those entering after 2 hr).
Together, these results confirm that 281816 inhibits the entry step
of HCV lifecycle.
After attachment to the cell surface and binding to entry factors,
HCV virions are internalized by clathrin-mediated endocytosis
[54,55]. Following internalization, HCV is transported to early
endosomes along actin stress fibers, where fusion seems to take
place [55,56]. To determine which step in HCV entry is impaired
by 281816, we administered the ligand at different intervals during
the early phase of infection. Virus attachment and binding were
performed at 4uC (Figure 6B, Steps 1 and 2), Then, cells were
shifted to 37uC to allow endocytosis and fusion (Figure 6B, Step 3).
Cells treated with JS-81 were used as controls. The addition of
281816 during step 2 and step 3 led to the strongest inhibition of
Table 2. Ligands predicted to bind to the HCV E2 protein by blind docking of the NCI Diversity Set III small molecule library to the
HCV E2 structural model and their predicted free energies of binding.
Ligand ID (NSC#) Free Energy of Binding (kcal/mol) Ligand ID Free Energy of Binding (kcal/mol)
670283 27.69 211490 28.7
86467 27.47 113486 26.26
639174 27.81 144694 27.27
81462 26.81 4429 27.3
403379 27.58 133071 27.5
213700 27.89 163910 27.4
359472 27.91 54709 27.3
146554 27.67 135618 28.7
204232 28.54 281254 26.5
281816 28.64 319990 27.4
308835 28.4 369070 26.3
60785 27.48 59620 27.3
84100 26.99 38968 23.9
158413 27.9 171303 25.8
57103 26.36 228155 28.7
121861 28.16 13316 26.8
3076 27.71 117268 27.6
doi:10.1371/journal.pone.0111333.t002
Figure 4. Surface plasmon resonance sensorgrams of ligands
binding to recombinant E2 protein (Biacore T100). This figure
shows sensorgrams (binding and dissociation plots) for three of the
ligands that bound to the recombinant E2 protein immobilized on a
CM5 chip, 281816 (black), 86467 (green) and 121861 (red), and the three
reference points that are used to measure the binding and dissociation
(dissociation 1 and dissociation 2) of the compound expressed in
response units (RU).
doi:10.1371/journal.pone.0111333.g004
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HCV infection, as strong as the one observed when 281816 was
present during all three steps. We also observed a significant
inhibition of HCV infection when 281816 was added during the
early attachment/binding steps (Figure 6B, Step 1). An MTS assay
performed with 10 mM 281816 for each length of time the cells
were treated with 281816 (1 hr, 2 hr, and 3 hr) showed the
compound was not cytotoxic to the cells under the conditions used
in the assay (Figure 7). Together, these results indicate that 281816
inhibits HCV infection by acting on more than the first
(attachment/binding) step of viral entry. These data suggest the
ligand also affects interactions during HCV internalization and
fusion.
Blocking of E2 binding to CD81
Ligand 281816 was originally selected for testing based on the
prediction by docking that it would bind to a site on the HCV E2
protein where CD81 binds. The infection assay conducted with
Huh-7 cells demonstrated 281816 is effective in inhibiting the
entry step in the HCV life cycle. To confirm that the binding of
281816 to E2 inhibits the HCV E2-CD81 interaction, flow
cytometry was used to monitor the binding of a recombinant form
of the E2 protein to native CD81 overexpressed on Raji cells as a
function of 281816 concentration. The results in Figure 8 show
binding of the E2 protein to Raji cells is inhibited by 281816 in a
dose dependent manner. Using a second technique (an ELISA-
based assay), we observed a similar dose-dependent effect of
281816 on the inhibition of the E2 protein binding to recombinant
CD81-LEL immobilized on micro titer plates (Figure 9). While an
IC50 for 281816 blocking the binding of E2 to CD81 could not be
determined from the flow cytometry data, the ELISA results
indicate the IC50 is in the range of 0.2–0.5 mM.
A blind docking experiment with 281816 has also suggested the
ligand may bind to several sites on CD81, including one that is
located within the region bound by E2. 281816 binding to CD81
or other cellular proteins could explain the 281816 retention
observed in washed cells in the HCV entry experiments. Such
binding would likely be of little consequence, unless the ligand
were to be bound within the E2 binding site on CD81 and were to
block the E2:CD81 interaction by targeting both proteins.
To determine if ligand 281816 also binds to CD81, surface
plasmon resonance was used to test for 281816 binding to
recombinant CD81-LEL protein immobilized on a chip. As shown
in Figure 10, 281816 does bind to CD81-LEL. A kinetic analysis
of this binding has shown that the ligand binds to CD81-LEL
(Kd = 57 mM) almost as well as it binds to E2 (Kd = 41 mM).
However, a competition ELISA experiment that used the anti-
CD81 antibody, 5A6, that blocks E2 binding to CD81 (Figure 11)
revealed that 281816 does not bind to the E2 binding site on
CD81. In this experiment, CD81-LEL was immobilized on a
micro titer plate and the binding of the 5A6 antibody was
monitored in the presence of 1 mM 281816 as a function of
antibody dilution. The antibody 5A6 has been shown previously to
bind to the same site on CD81 recognized by E2 [57,58] with an
affinity (75 nM) [59] about 1/10th that of E2 (4–10 nM) [60,61].
Table 3. Magnitude of surface plasmon resonance binding response obtained for the 23 ligands that were identified to bind to
recombinant E2 protein immobilized on a CM5 sensor chip.
Ligand ID (NSC#) Binding (RU) Dissociation 1 (RU) Dissociation 2 (RU)
670283 54.3 4 1.4
86467 54.9 1.9 0.8
639174 55.4 2.3 0.6
81462 57.2 9.2 6.5
403379 58 2.8 1.1
213700 62 3.1 0.8
359472 62 2.5 0.8
146554 63.4 3.1 0.8
204232 63.4 2.5 0.4
281816 64.5 3.7 0.9
308835 64.8 7.1 5.2
60785 70.4 2.8 0.6
84100 71.2 4.2 2.2
158413 71.2 10.3 8.5
57103 81.6 11.4 2.5
121861 88.4 26.1 20.4
117268 88.5 4.1 1.2
3076 92.2 3.2 1.6
211490 102.9 6.1 2.1
113486 104.7 7 2.6
144694 118.8 6 2.3
4429 155.3 28.9 14.2
133071 276.3 1.8 22
The rate of ligand dissociation is assessed by measuring the response units at two time points (10 sec and 50 sec) after the chip with bound ligand is rinsed with buffer.
doi:10.1371/journal.pone.0111333.t003
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Working at the same concentration of 281816 (1 mM) that
provided the best inhibition of E2 binding to CD81-LEL,
281816 did not inhibit the 5A6 antibody binding to CD81 even
when the antibody concentration was reduced to 1/2000th the
concentration of the ligand (Figure 11). The amount of 5A6
antibody bound to CD81 remained the same in the presence and
absence of the ligand, demonstrating that 281816 does not bind
sufficiently well to the E2 binding site on CD81 to block 5A6
binding.
Figure 5. 281816 inhibits HCV entry in a genotype-independent manner. (A) Huh-7 cells in 96-well plates were pre-treated with 281816 (left
and middle panels) or anti-CD81 antibody (right panel) at the indicated concentrations and then infected with HCVpp 2a or HCVcc. (B) Huh-7 cells in
24-well plates were pre-treated with 281816 at the indicated concentrations and infected with HCVpp expressing envelope proteins from the
indicated genotype. After 30 hr of infection, cells were lysed and luciferase activities quantified. HCVpp infections were normalized to RD114pp
infections.
doi:10.1371/journal.pone.0111333.g005
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281816 abrogates HCV cell-to-cell transmission
In addition to cell-free infection, HCV can also be transmitted
to neighboring cells via cell-to-cell contact by a mechanism that is
not completely understood [41,42,62]. Indeed, HCV is transmit-
ted in the presence of monoclonal antibodies, such as the anti-E2
antibody 3/11, or patient-derived antibodies that are able to
neutralize virus-free infectivity [42,62]. Since cell-to-cell transmis-
sion has been suggested to be a major route of transmission for
HCV [41], we next analyzed the effect of 281816 on this process.
For this purpose, Huh-7 cells were infected at low multiplicity of
infection with HCVcc for 2 hr and then cultured with neutralizing
anti-E2 antibody (3/11), which blocks infection by free particles as
shown in Figure 12 [41], and in the presence of 281816 (1 mM
and 10 mM). Cells cultured in the presence of 3/11 and solvent
(DMSO) or Epigallocatechin-3-gallate (EGCG, 50 mM) [42] were
used as negative and positive controls of inhibition, respectively.
Three days post-infection, cells were fixed and foci of infected cells
were visualized by immunofluorescence. Cell-to-cell transmission





670283 3 ND ND
86467 .10 .10 .10
639174 0.03 ND ND
81462 .10 .10 .10
403379 .10 .10 .10
213700 .10 .10 .10
359472 .10 .10 .10
146554 .10 ND ND
204232 .10 .10 .10
281816 .10 1.02 3.95
308835 .10 .10 .10
60785 3.5 ND ND
84100 .10 .10 .10
158413 .10 .10 .10
57103 0.3 ND ND
121861 .10 .10 .10
117268 0.1 .10 .10
3076 0.25 ND ND
211490 0.5 ND ND
113486 .10 .10 .10
144694 .10 .10 .10
4429 .10 .10 .10
133071 0.10 ND ND
Anti-CD81 .10* 0.17* 0.36*
ND refers to molecules that were not assayed because the molecule was not specific for HCV (it inhibited RD114pp infection). *IC50 values for anti-CD81 antibody are in
mg/ml.
doi:10.1371/journal.pone.0111333.t004
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Figure 6. 281816 inhibits HCV entry. (A) Huh-7 cells in 24-well plates were treated at different time points with 281816 at 10 mM and infected
with HCVcc for 2 hr at 37uC. 281816 was added full-time during the experiment (a), 2 hr before virus inoculation (b), 2 hr during virus inoculation (c),
or full-time after virus inoculation (d). (B) Huh-7 cells were infected with HCVcc for 1 hr at 4uC (Step 1: attachment/binding), then virus was removed
and cells incubated again at 4uC for 1 hr (Step 2: post-attachment/binding). Finally, cells were shifted at 37uC for 1 hr (Step 3: endocytosis/fusion) and
left at 37uC for 21 hr. 281816 was added at 10 mM either during the Step 1, Step 2, Step 3 or Steps 1-2-3. * and *** indicate p values below 0.05 and
0.0001, respectively.
doi:10.1371/journal.pone.0111333.g006
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was measured by counting the number of infected cells per focus.
The results showed that 281816 led to a significant reduction of
the number of infected cells per focus in a dose-dependent manner
(Figure 13). Together, these results indicate that 281816 also
inhibits cell-to-cell transmission of HCV.
Discussion
While it has been known for some time that the E2 envelope
glycoprotein plays an important role in the life cycle of HCV, we
are only now beginning to learn details about the structure of the
E2 and how it functions. This has been attributed to the
challenging intrinsic properties of the protein, such as the presence
of multiple flexible loops, its tendency to form disulfide aggregates
in solution and the high level of N-linked glycosylation, all of
which make it difficult to determine it’s structure. Neutralizing
antibody epitope analyses and mutation studies, in contrast, have
provided a great deal of information about the regions of the E2
protein and specific amino acids that participate in CD81 binding
and are important for HCV infectivity [9].
The recent determination of two HCV E2 protein core crystal
structures [18,19] and our use of the deposited coordinates to
create a new homology model of the protein’s structure containing
the majority of conserved amino acids and peptide segments
known to be important for viral invasion of hepatocytes has made
it possible to use computational docking and structure-based drug
design methods to begin developing anti-HCV drugs that target
the conserved regions of E2 and block its interaction with host
receptors. Our docking of a library of diverse small molecules to
this homology model led to the identification of a set of ligands
that were predicted to bind to sites near key amino acids known to
participate in CD81 or E1 binding or to block HCV infection, and
23 of the 34 compounds were confirmed by experiment to bind to
recombinant E2 protein. When these 23 ligands were tested for
activity in blocking HCV infection of Huh-7 cells, only ligand
281816 was found to inhibit HCV infection using both HCVcc
and HCVpp based assays. Upon analyzing the activity spectrum of
HCV using HCVpp bearing envelope proteins from different
HCV genotypes (1a, 1b, 2a, 2b, 4a and 6a), 281816 was found to
inhibit the infection of all tested genotypes with IC50’s ranging
from 2.2 mM to 4.6 mM (Table 5), indicating that this small
molecule inhibits HCV infection in a genotype-independent
manner. Ligand 281816 was also observed to block the binding
of HCV E2 protein to CD81-LEL protein and to Raji cells
expressing CD81.
The docking experiments conducted with 281816 identified the
two binding sites on E2 shown in Figure 14. One cluster of 281816
conformers bound deep inside a cavity positioned directly above
Y618 and P619, two amino acids in site 4 (Figure 3) that are
Figure 7. Viability of Huh-7 cells treated with 281816 in the
HCV entry experiments. An MTS assay [38] was used to determine
the viability of cells treated with 10 mM 281816 in DMSO (and DMSO
alone, as a control) for 1 hr, 2 hr, or 3 hr under the same conditions
used in the HCV entry experiments. 281816 is not toxic under any of the
conditions used in this assay. There were no significant differences
between the 281816 treated and control samples (p values ,0.05).
doi:10.1371/journal.pone.0111333.g007
Figure 8. 281816 inhibition of HCV E2 protein binding to
native CD81 on Raji cells. Flow cytometry was used to quantify
recombinant HCV E2 protein binding to native CD81 over-expressed on
Raji cells. Binding of the recombinant E2 protein to native CD81 on the
surface of Raji cells was detected using the mouse monoclonal E2
antibody clone H53 followed by staining with a secondary FITC anti-
mouse antibody. E2 binding is inhibited by 281816 in a dose-
dependent manner up to 100 mM.
doi:10.1371/journal.pone.0111333.g008
Figure 9. Ligand 281816 inhibits HCV-E2 binding to recombi-
nant CD81-LEL. Binding of recombinant E2 protein to GST-tagged
human CD81-LEL immobilized on a 96 well plate was determined using
an ELISA assay. The plate was coated with GST-tagged human CD81-LEL
(5 mg/ml) overnight as previously described [10], HCV E2 protein (5 mg/
ml) was pre-incubated with different concentrations of 281816 for
30 min before adding to the plate, and the HCV-E2 protein (with or
without the ligand) was then added to the GST-tagged human CD81-
LEL coated plate and incubated for 1 hr. HCV-E2 binding was detected
using a primary mouse anti-E2 antibody (H53 clone) and a secondary
goat anti-mouse-HRP antibody by measuring the absorbance at
405 nm. The results, which are plotted as percent of E2 protein bound
to CD81-LEL relative to E2 binding observed in the absence of the
ligand (buffer control), show a dose-dependent effect of 281816 on the
inhibition of the E2 protein binding to immobilized recombinant CD81-
LEL. P values for the 0.05, 0.2, 0.5 and 1.0 mM 281816 samples are
0.0069, 0.0195, 0.0006 and 0.0009 respectively.
doi:10.1371/journal.pone.0111333.g009
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known to contribute to E2’s binding to CD81 [47]. The two
strongest 281816 ligand binding modes are shown bound to this
site. 281816 was also predicted to bind to a shallow cavity on the
opposite side of the protein. These conformers were predicted to
bind to site 1 near residues V515, G517, P515 and H421–N423.
H421–N423 is part of a larger segment of E2 that has been shown
to bind to CD81 [19]. As expected, the ligand positioned above
Y618 and P619 in the deeper cavity was predicted to bind more
strongly to this region of the protein (free energy of binding of the
best bound ligand =28.64 kcal/mol) than when it was bound to
the shallow cavity on the other side of the protein (free energy of
binding =26.39 kcal/mol).
A subset of the 281816 conformers in the cluster observed to
bind near site 4 overlapped into site 2 and bound immediately
adjacent to D481–P490, part of the epitope targeted by antibodies
that block HCV infectivity and E2 binding to CD81 [50]. W487, a
residue within this peptide segment whose mutation has been
shown to disrupt E2:E1 dimerization [63], is also located near site
2. Other conformers in the cluster binding to site 1 also overlapped
into site 5 and bound near amino acid residues P612 and Y613.
These docking results illustrate one interesting and unique feature
of the 281816 ligand; a number of its conformers are predicted to
bind immediately above or next to both exposed faces of the
P612–P619 amino acid residues that are known to participate in
E2 binding to CD81 [47].
One factor that can have a significant impact on the accessibility
of these sites to the binding of 281816 and other ligands is the
oligomeric state of the native E2 protein. Analyses of the E2
protein and its complexes have shown that the protein exists in
several different oligomeric states [43,64–73]. These include non-
covalent heterodimers of E1 and E2, large disulfide cross-linked
E2 complexes and aggregates, as well as monomers and disulfide
linked E2 homodimers. E1E2 non-covalent heterodimers are
formed in infected cells [70–72], and it has been proposed that the
two proteins remain as a complex on the virus surface, perhaps
covalently linked through an intermolecular disulfide bond located
in their transmembrane regions [69]. Large covalent complexes
containing E2 stabilized by multiple disulfide bonds have also been
observed to be associated with the surface of infective virions [71].
It has been hypothesized that the disulfide crosslinks in these large
complexes may contribute to the structural stability of the virion. It
has also been proposed that these large complexes may play a role
in budding. Other large disulfide cross-linked aggregates of E2
have been found in recombinant E2 expression systems [74–78]
and in the endoplasmic reticulum, but these aggregates do not
Figure 10. Single cycle kinetics of 281816 binding to recom-
binant HCV E2 and his-tagged CD81-LEL. Using surface plasmon
resonance detection, ligand 281816 is observed to bind to both HCV E2
and CD81-LEL proteins immobilized on a CM5 chip. Analyses of the
binding kinetics were used to obtain dissociation constants for 281816
binding to recombinant E2 (Kd = 41 mM) and recombinant his-tagged
CD81-LEL (Kd = 57 mM) protein.
doi:10.1371/journal.pone.0111333.g010
Figure 11. Ligand 281816 does not compete with binding of an
anti-CD81 antibody to human CD81-LEL. Binding of anti-CD81
monoclonal antibody 5A6 to recombinant GST-tagged human CD81-
LEL protein was determined by ELISA. Serial dilutions of 5A6 antibody
were incubated with the CD81-LEL protein in the presence of 1 mM
ligand 281816 (black squares) or PBS as a control (open circles). The
amount of 5A6 antibody bound to CD81 remained the same in the
presence and absence of the ligand, demonstrating that 281816 does
not bind sufficiently well to the E2 binding site on CD81 to block 5A6
binding, even when the antibody concentration was reduced to 1/
2000th the concentration of the ligand.
doi:10.1371/journal.pone.0111333.g011
Figure 12. Cell-free infection of Huh-7 cells by HCVcc is
blocked by the anti-E2 antibody 3/11. HCVcc were pre-incubated
for 1 hr with neutralizing anti-E2 monoclonal antibody 3/11 at a
concentration of 50 mg/ml and next inoculated to Huh-7 cells for 2 hr.
Three days post-infection, cells were fixed, stained with the mouse anti-
E1 antibody A4 and Alexa555 conjugated anti-mouse IgG, and the
number of infected cells was counted. The results show the anti-E2
antibody 3/11 effectively blocks cell-free infection of Huh-7 cells by
HCVcc.
doi:10.1371/journal.pone.0111333.g012
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appear to represent a functional or biologically relevant oligomeric
state.
E2 is known to be heavily glycosylated [69,79,80]. In the
HCVcc system E2 has been reported to have 11 glycosylated sites
that collectively account for nearly half the mass of the protein
[69,79,80]. Glycosylation of a number of these sites has been
shown to prevent the binding of neutralizing antibodies to E2 and
to block E2 binding to CD81 [81], Although the ligands identified
in this study are much smaller than antibodies or CD81, the
presence of the glycans could also prevent small molecules from
binding to the protein’s surface if the glycosylated amino acid
residues are located close to the ligand binding site.
While the oligomeric structure of E2 on the surface of the HCV
virus is not known, the E2 present in the virus and pseudoparticles
does bind to both recombinant CD81-LEL and the native CD81
receptor present on hepatocytes. Since each of the five ligand
binding sites on E2 we used in our docking experiments contain or
are located immediately adjacent to amino acid residues that are
known to participate in E2 binding to CD81, ligands targeting
these sites should have access to bind in the cavities. In addition, a
number of these binding sites are located within epitopes
recognized by antibodies that inhibit HCV infectivity, providing
an additional confirmation of the accessibility of the sites. Only
one of the 11 known glycosylated amino acid residues, E2N7, is
located near a ligand docking site (Site 3). Our docking studies
have identified 281816 ligand conformers that are predicted to
bind to sites 1 and 4 and a few that overlap into sites 2 and 5, but
none are expected to bind to Site 3. This suggests that the binding
Figure 13. 281816 blocks HCV cell-to-cell transmission. Huh-7
cells were seeded on coverslips and infected with HCVcc for 2 hr at
37uC. Cells were then washed and cultured for 72 hr at 37uC in culture
medium containing the 3/11 neutralizing antibody (50 mg/ml) in
presence or in absence of 281816 at indicated concentrations. Cells
cultured in presence of DMSO or EGCG at 50 mM were used as controls.
The number of infected cells per focus was determined by A4 indirect
immunofluorescence. The results show treatment with 281816 signif-
icantly reduces the number of infected cells per focus in a dose-
dependent manner. Mean p values were below 0.001 for 1 mM 281816
and below 0.0001 for the 10 mM 281816 and EGCG treatment groups.
doi:10.1371/journal.pone.0111333.g013
Figure 14. Relative location of 281816 binding sites 1 and 4 on HCV E2. 281816 (structure, top) is predicted to bind to two sites on the E2
protein. Two conformers of 281816 with the lowest free energy of binding are shown bound to site 4. The conformer with the lowest free energy of
binding to site 1 is also shown. A video showing the surface structure of the E2 homology model with the three 281816 conformers bound that
rotates 360u can be found in Movie S1.
doi:10.1371/journal.pone.0111333.g014
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of 281816 and its analogs should not be affected by glycosylation.
The limited proteolysis and deuterium exchange experiments
conducted with the E2 protein core and reported by Khan et al.
[19] also indicate that each of the five ligand docking/binding sites
is accessible and exposed to solvent – an important prerequisite for
ligand binding.
To probe more deeply into the inhibition of the infection
process by 281816, experiments were conducted to determine if
the inhibition of cell-free infection by 281816 might be limited to
viral entry, which step in the entry process might be affected by the
compound, and what impact, if any, 281816 might have on cell-to-
cell transmission of HCV. Analyses of Huh-7 cells inoculated with
HCVcc before, during or after treatment with 281816 revealed the
compound only blocks HCV entry and does not inhibit post-entry
processes in the HCV life cycle. A kinetic analysis of the effect of
281816, coupled with a temperature block to endocytosis and
fusion, was used to examine the cell-free entry steps in more detail
and showed 281816 inhibits not only the initial attachment/
binding step, but it also has an effect on interactions that occur
later during viral internalization and fusion. Ligand 281816 was
also observed to abrogate the cell-to-cell transmission of HCV.
281816 treatment of Huh-7 cells cultured in the presence of the
anti-E2 neutralizing antibody 3/11 not only led to a dose
dependent reduction in the number of cells forming foci, but it
was found to be more effective in blocking cell-to-cell transmission
that the Epigallocatechin-3-gallate [42] used as a positive control.
The observation that some 281816 remained bound to cells
after washing in the HCV entry experiments suggests that 281816
may bind to other cellular proteins. This should not be surprising,
since this compound has been reported to have other activities
[82–87]. A blind docking experiment performed with 281816 also
predicted the ligand could bind to CD81. Three potential binding
sites were identified, one located within the E2 binding site on
CD81 and two others in regions that would not be expected to
impact E2 binding. Collectively these observations suggested the
exciting possibility that 281816 might play a dual role in blocking
E2 binding to CD81 by binding not only to the CD81 binding site
on E2, but also by binding to the E2 binding site on CD81. In
support of this idea, results obtained in an SPR binding study
showed 281816 bound to CD81 almost as well as it bound to E2.
However, a subsequent competition experiment conducted with
281816 and a monoclonal antibody (5A6) known to bind to the E2
binding site on CD81 revealed that the ligand did not compete
with the antibody. One micromolar 281816, which effectively
blocks E2 binding to CD81-LEL and inhibits viral invasion of
Huh-7 cells, had no effect on antibody 5A6 binding to CD81-LEL.
In addition to identifying a promising new small molecule drug
lead for treating HCV that targets the E2 glycoprotein, this study
also demonstrates the utility of our new E2 homology model in the
discovery of small molecules that bind to important sites on E2. By
targeting sites containing amino acid residues identified by others
to participate in CD81 binding and CD81-dependent processes
that impact HCV infectivity, a small molecule was identified that
not only blocks E2 binding to CD81 and the cell-free entry
process, but it is also effective in blocking the cell-to-cell
transmission of HCV – the predominant mechanism of transmis-
sion that contributes to the persistence of infections [41] but for
which the precise mechanism needs to be defined. Recently, it has
been shown that exosomes produced by HCV infected hepatic
cells can transfer viral RNA to plasmacytoid dendritic cells [88]
and might transmit infection to naı¨ve hepatic cells [89]. Although
several entry factors have been implicated in this process, the viral
determinants, entry factor requirements and molecular mecha-
nisms involved in cell-to-cell transmission route still need to be
further characterized. In particular, the role played by CD81 has
remained controversial with studies reporting HCV cell-to-cell
transmission as a CD81-dependent pathway [41,90,91], whereas
others demonstrated a CD81-independent transmission
[56,62,92]. However, a recent study has highlighted the coexis-
tence of CD81-dependent and CD81-independent cell-to-cell
transmission [93]. The inhibition of cell-to-cell transmission of
HCV by 281816, which blocks E2 binding to CD81, is consistent
with other reports of a CD81-dependent cell-to-cell transmission
process [93–94] that can be blocked by anti-CD81 antibodies
[41,94] and soluble CD81 [56], both of which also block E2
binding to CD81. While it is possible that E2 binding to CD81
may play a role in the cell-to-cell transmission of HCV, it is also
possible the 281816 that binds to CD81, which does not inhibit E2
binding, may have a totally unrelated effect that impacts the
interaction of CD81 with other proteins or molecular structures in
the tetraspanin web [95,96] and blocks fusion related events
involving CD81 that occur during the cell-to-cell transmission
process.
281816, known as methiothepin or 1-methyl-4-(3-methylsulfa-
nyl-5,6-dihydrobenzo[b] [1]benzothiepin-5-yl)piperazine, is also
interesting because it has been determined previously to block
dopamine [82] and serotonin [83] receptors and has been reported
to inhibit a number of other biological activities, which include the
binding or entry of two other unrelated viruses into cells (Lassa
[84], Marburg [85]), Plasmodium falciparum proliferation [86],
and Mycoplasmodium tuberculosis infections [87]. Numerous
structural analogs of 281816 have been tested and shown to be
effective in treating a wide variety of neurological diseases
(schizophrenia [97,98], Parkinson and dementia-related psychoses
[99,100]), bipolar disorders [101,102], and depression [103,104].
While we have not found experimental studies that report the
membrane permeability of 281816, the logP (log of octanol/water
partition coefficient) has been calculated to be 4.14, which
indicates the compound is likely to exhibit good membrane
permeability. Since the logP is less than 5, according to Chris
Lipinski/Pfizer’s Rule of 5 the compound could also be orally
active, as are a number of 281816 structural analogs (octoclothe-
pine, loxapine, amoxapine, clozapine, quetiapine, olanzapine, and
amitriptyline) that have been used to treat a variety of neurological
disorders.
Supporting Information
Table S1 Table showing lowest free energies of binding
obtained for all 1,715 ligands docked to the E2 homology
model.
(DOCX)
Movie S1 Conformers of ligand 281816 exhibiting
lowest free energies of binding are shown bound to sites
4 and 1 on the E2 homology model.
(MOV)
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